Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.
Introduction
Positron emission tomography (PET) is an imaging technology that delivers high-resolution images using biologically active compounds, substrates, ligands or drugs labelled with positron emitters [1] . These radiolabelled agents are primarily administered intravenously, distributed according to blood flow and utilized or processed in a manner virtually identical to their non-radioactive counterparts. They produce images and quantitative indexes of blood flow, glucose metabolism, amino acid transport, protein metabolism, neuroreceptor status, oxygen consumption or even cell division, etc. Since only tracer level amounts of material are administered, no pharmacological effect occurs and there is no perturbation of the targeted biochemical process [2] [3] [4] . Diagnosticians have traditionally been trained to analyse information provided by structural or anatomically based techniques. Biochemical processes are, however, altered in virtually all disease states and these alterations usualCorrespondence to: R Rigo, Nuclear Medicine, C.H.U. Sart Tilman, B.35, B-4000 Liege 1, Belgium ly precede gross anatomical changes. With the advent of molecular biology-based medicine, a transition must be made to incorporate information based on biochemical perturbations into diagnostic information, without waiting for structural changes. PET is one of the few clinical imaging techniques that provides such information. PET is also a very useful adjunct to anatomical imaging techniques, providing unique information and an additional dimension to the characterization of disease [5] .
While applications initially focussed on the brain and the heart, PET is now primarily used in oncological indications. This development has resulted from the successful application of fluorine-18 fluorodeoxyglucose (FDG) to a growing number of clinical indications at varying stages of diagnosis, staging and therapy follow-up of patients with cancer of many types and origins [6] [7] [8] .
FDG uptake in cancer tissue is well documented in the literature and is based upon the increased glycolysis that is associated with malignancy as compared with most normal tissues [9, 10] . The availability of a radioactive glucose analogue and of PET has allowed the study of glucose uptake in vivo. Initial work focussed on primary brain tumours as brain PET scanners were most commonly available. Di Chiro [11] first demonstrated that FDG PET was able to discriminate brain tumour recurrences from post-therapy changes. PET also provides a method to assess tumour grade and to evaluate patients' prognosis. With the advance of the whole-body imaging unit, the FDG technique has blossomed.
It is therefore appropriate to review the advantages and limitations of FDG as a tumour-seeking agent, its present and potential clinical role, the requirement for clinical improvement and widespread application of PET, and certain research perspectives.
Biological characteristics of 18-FDG
Use of FDG for in vivo cancer imaging is based on the observation of enhanced glycolysis in tumour cells. A high rate of "aerobic glycolysis" (degradation of glucose to lactic acid in the presence of oxygen) in several types of cancer cells was first described by Warburg [12, 13] . This phenomenon has been linked to both an increase in the amount of glucose membrane transporters [14] and an increase in the activity of the principal enzymes controlling the glycolytic pathways.
Uptake of glucose and FDG into malignant cells is facilitated by an increased expression of the glucose transporter molecules at the tumour cell surface. Five transporters (GLUT1-GLUT5) are currently known and distributed in variable quantities among different tissues. GLUT1 and GLUT3 are the most frequent. GLUT4 depends on insulin for activation. Several papers suggest that activation of the gene coding for synthesis of the glucose transporter GLUT1 is a major early marker of cellular malignant transformation [15] [16] [17] [18] [19] [20] .
GLUT1 messenger RNA indeed increases 3-4 days before morphological transformation and this increase is not correlated with the cell proliferation rate [21] [22] [23] . Transfection to rat fibroblast of activated ras or src oncogenes results in an elevation of the cytosolic concentration of mRNA responsible for the synthesis of glucose transporter [24] . In addition, an increased concentration of the mRNA has been linked to the increase in the number of glucose transporters in the malignant cell. In man, overexpression of GLUT1 and GLUT3 has been observed in several tumour types, including cerebral tumours, hepatocellular carcinoma and pancreatic tumours [25] [26] [27] [28] . Furthermore, an increase in the activity of several enzymes controlling the glycolytic pathway has been demonstrated (hexokinase, phosphofructokinase, pyruvate dehydrogenase) [29] . For instance, several isoenzymes of hexokinase have been observed in the Novikoff ascites tumour [30] .
FDG following intracellular transport is a substrate for hexokinase, the first enzyme of glycolysis. It is phosphorylated to FDG-6-phosphate. However, the second enzyme, glucose-6-phosphate isomerase, which transforms glucose-6-phosphate into fructose-6-phosphate, does not react with FDG-6-phosphate. Further, as the concentration of glucose-6-phosphatase is very low (except in the hepatocyte), the reverse transformation is not possible and FDG-6-phosphate remains trapped. Accessory metabolic pathways to gluconate and glucuronate are very slow and can be considered negligible within the time frame of the t8F half-life. The cellular concentration in 18F is therefore closely representative of the accumulated FDG-6-phosphate and of the glycolytic activity of exogenous glucose [31, 32] .
Numerous studies have attempted to relate cellular FDG uptake to the biological properties of the tumour such as the histological grade, the proliferative activity, the doubling time and the number of viable turnout cells. A positive correlation between FDG uptake and the tumour grade has been reported in several tumour types including cerebral gliomas [33] , liver tumours [34] , nonHodgkin's lymphomas [35, 36] and some musculoskeletal tumour types [37, 38] . The relationship between tumour grade and uptake is, however, less marked in pulmonary tumours [7] . In hepatocellular carcinoma, the growth rate and the activity of glycolytic enzymes are related [39] . In head and neck turnouts, the proliferative activity studied by DNA flow cytometry is related to FDG uptake while FDG does not reflect the turnout type. Further different cells of similar proliferative activity appear to belong to two different groups based on FDG uptake, suggesting the influence of other factors [40] . In cultured human ovarian adenocarcinoma cells, FDG uptake is not related to proliferative activity but to the number of viable tumour cells [41] . In subcutaneously transplanted tumour cells, Kubota et al. [42] analysed the intratumoral distribution of FDG and tritiated deoxyglucose. Both tracers had a similar distribution pattern within the tumour with both autoradiographic methods. A maximum of 29% of glucose utilization was derived from non-tumorai tissue. It was concentrated in granulomatous tissue and macrophages infiltrating the areas surrounding necrotic tumoral tissue. High accumulation of FDG in the tumour is believed to represent high metabolic activity of the viable tumour cells [43, 44] .
It is important to stress that FDG uptake by neoplastic turnouts in vivo remains under the dependence of other physiological factors, such as tissue oxygenation, regional blood flow and peritumoral inflammatory reactions [45] [46] [47] [48] . FDG PET therefore must be considered as a very sensitive technique, but a technique whose specificity is imperfect and must be compensated for by careful selection of patients and rigorous correlation with anatomical images (including image fusion, whenever possible) [49] .
Other tracers designed to evaluate amino acid uptake (carbon-ll methionine) [44, [50] [51] [52] , protein synthesis (1JC-tyrosine) [53] or DNA synthesis and cellular proliferation (llC-thymidine and 18F-fluorodeoxyuridine) [46, 54] have been proposed as tumour imaging agents. However, less experience has been accumulated using these tracers. While theoretically attractive, they are more difficult to produce and usually do not provide the same image contrast that makes FDG so impressive (with the notable exception of J lC-methionine for brain turnouts). Use of tracer modelling technique is required and in particular, labelled metabolites in blood and tissues have to be taken into account. For instance, no adequate model is yet available for HC-thymidine while it is now recognized that a significant part of the signal in tissues is related to accumulation of 11CO2 ! [55] .
Kubota et al. [50, 51] have compared the tumoral uptake of methionine (using 14C-methionine in place of 11C-methionine) and FDG using the same tumour models or experimental conditions for both tracers. 14C-Methionine uptake within viable tumour cells is relatively more important than the uptake of FDG. Indeed, FDG is taken up not only by viable tumour cells but also by the peritumoral granulation tissue, by activated macrophages within the turnout and by cells at the periphery of necrotic tumoral tissue. These observations suggest that l~C-methionine could give false-negative results when studying tumours with few active tumoral cells but massive macrophage infiltration. On the other hand, during follow-up of therapy, and especially of radiotherapy, in the presence of numerous activated macrophages and prenecrotic tumoral~ cells, FDG could remain increased in the absence of proliferating tumoral cells. The choice between these two tracers therefore depends on the type of tumour studied and on the aim of the test. In general, to differentiate between benign and malignant tissues, FDG should provide more sensitive results than l lC-methionine [31, 50, 51] .
A similar comparison has been performed by Minn et al. [44] using different models derived from three cellular lines from head and neck epidermoid epithelioma. Indeed, the proliferation kinetics of head and neck tumours has important implications concerning the irradiation schemes. The uptake of FDG and of 14C-methionine appears in that study to be well correlated to the pool of viable cells. Absolute methionine uptake, however, is smaller than that of FDG, especially during the exponential and plateau proliferation phases, leading to relative underestimation of the number of tumoral cells when using methionine. These two studies confirm the potential advantage of FDG for the study of the pool of viable cells. Methionine, on the other hand, appears superior for evaluation of the number of proliferative cells. I ICmethionine could prove more favourable for evaluation of therapeutic efficacy, especially after radiotherapy.
Other investigators have pointed out, however, that methionine, although a tracer of amino acid uptake, is not a tracer of protein synthesis, and they propose the use of ~lC-tyrosine instead, l~C-tyrosine would indeed be better suited to kinetic modelling of protein synthesis, but experimental and clinical uses of this tracer are only beginning [56] .
Methodological considerations
The field of view of the PET camera is usually quite limited as these instruments were initially developed for the heart and the brain, and because of cost constraints. It varies between 10 and 16 cm in most scanners, with the largest field of view for a single acquisition being in the order of 25 cm. Most scanners consist of BGO or NaI crystals and the number of slices depends on the physical size of the sampling elements and/or on the size of the digital matrix [57] [58] [59] . Resolution typically varies between 4 and 6 mm FWHM depending on the performance of the unit. An important consideration is the achievement of isotropic resolution and avoidance of off-centre degradation, necessary for successful image reorientation. Effective clinical resolution can be further degraded by count statistics and the use of smoothing filters. It is more typically around 6-10 mm depending on the instrument used. The use of single-photon emission tomographic (SPET) cameras with high-energy collimators remains unproven in oncology [60] while the use of dual-head large field of view cameras with coincidence correction now appears feasible [61] .
Instrument sensitivity is more important than count rate for whole-body PET and oncology as it allows optimal use of frequently limited tracer amounts, and directly influences scanning time. The advent of 3D-imaging capability has markedly increased the sensitivity of current scanners and allowed an increase in the signal to noise ratio while reducing the amount of tracers needed.
Whole-body imaging is performed by successively displacing the patient bed over 1/2 to 1 time the field of view [62] . Some degree of overlap is preferable, especially in the 3D-mode, to even out z-axis sensitivity changes due to varying effective axial incidence angle over the field of view and to avoid zip artefacts caused by patient motion or by overcompensation of sensitivity variations at the edges of the field. Use of bed displacement of 1/2 the field of view interval does not prolong the acquisition time as sampling remains homogeneous over the whole body.
Attenuation correction is necessary for quantitative tracer uptake determination [63, 64] . It is usually performed using transmission images. These are most necessary over the thorax, where important variations in tissue density are expected [65, 66] . Transmission data are, however, less critical over the brain and the abdomen. In these regions, attenuation can be calculated using body contours assuming a uniform tissue attenuation. Errors resulting from this assumption may be less critical than errors resulting from incorrect attenuation measurements by inadequate (short, count deficient) transmission scans. Similar considerations have prompted the introduction of transmission image segmentation for attenuation correction in the thorax. Segmentation traces the contours of the patient as well as of the imaging table. It determines the limits of the lungs and optionally of the spine and substitutes a known attenuation coefficient for the measured attenuation correction. This approach decreases the artefacts produced by the statistical noise in the transmission image and allows a reduction in transmission imaging time. Routine attenuation correction is usually not performed in the whole-body mode and such an approach may be necessary for its routine implementation.
Currently quantitative data are usually obtained using detailed dynamic imaging followed by static imaging using pre-injection attenuation correction [67] . Another technique introduced to optimize acquisition time and scanner utilization is the use of post-injection and postemission transmission corrections. This approach is made possible by the use of a rotating rod source [68] . Knowledge of the position of the source allows exclusion of most of the emission events whose line of coincidence is not co-linear with the source. The rate of emission events co-linear with the source can be estimated by the use of a mock transmission source positioned at a fixed angle from the real source and a similar event rate can be subtracted. This approach has been validated Fig. 1 . Normal distribution of FDG uptake by phantom and patient studies. It allows significant shortening of total patient time in the scanner and decreases considerably motion artefacts in attenuation corrected images [69] .
A high-energy single-photon emitter (cesium-137, 667 key) has been proposed as a transmission source to increase count rate to the distant crystal [63] . Saturation of the nearby crystal is no longer a problem as true coincidence imaging is not perlbrmed ("coincidence" is between the source position and its interactions on a distant detector) and the near detectors are protected by shielding. Preliminary results indicate a considerable reduction in transmission acquisition time using this system. Another approach is the use of computed tomography to measure the transmission data. Technological advances have reduced the cost of CT and hybrid machines are now being considered. In addition, this approach could provide optimal matching between anatomical and biochemical images.
Visual qualitative assessment of whole-body PET imaging is usually quite satisfactory [70] . Yet quantification is desirable. The rate of tracer uptake over time can be determined using dynamic images. If the blood tracer activity over time is also available [obtained by arterial sampling or in a large vessel region of interest (ROD], a compartmental modelling tracer kinetic approach can be used [32] . A three-comparment model is usually used with FDG. The Patlak-Gjedde graphical approach can also be applied using dynamic data to estimate the rate of influx of FDG in quantitative terms [71] . Both approaches require assumptions regarding the lumped constant. Yet this has not been assessed in tumours and would be difficult to determine given tumoral uptake heterogeneity.
Simple semi-qualitative analysis is now frequently performed using tumour to non-tumour uptake ratios or preferably by determining the standardized uptake ratio (SUV), which relates the concentration in the tumour to the average concentration in the body considered as unity. Generally the higher the value, the more likely it is that tumour is present. Conceptually simple, the SUV is more difficult to apply to whole-body than static imaging as its requires multiple corrections (for decay, attenuation, scatter, randoms, dead time, etc.) [70, [72] [73] [74] [75] . Yet it remains poorly standardized as it is still dependent on many factors including glucose level, weight and fat body content, time after injection, ROI size and scanner resolution (partial volume effect) [76] [77] [78] . The SUV rises over time in most untreated tumours and standardization of imaging time is important in quantitative studies. SUVs from different institutions with different scanners or imaging protocols cannot necessarily be compared.
The normal distribution of the tracer is illustrated in Fig. 1 . The uptake predominates in the brain, where the grey matter avidly concentrates FDG irrespective of the metabolic conditions. Myocardial uptake is variable and depends on substrate availability. The kidneys concentrate and eliminate FDG, which therefore accumulates in the urinary outflow tract and bladder. Moderate uptake is noted around the eyes, mainly in the oculomotor muscles, in the mucosal, muscular and lymph node tissue of the mouth, nasopharynx and pharynx, and in the liver, spleen and bone marrow. Activity varies markedly in the gastrointestinal tract. Some increase is usually noted in the region of the stomach, but colonic uptake can be quite significant, mainly around the hepatic and splenic angles and in the sigmoid [79, 80] . Muscular activity is also quite variable [77] and can be prominently increased in the case of muscle tension or utilization around the time of injection. Complete rest (no walking, no reading, no chewing, no speaking) is indicated and the use of diazepam may be necessary in some tense subjects to avoid muscle uptake artefacts. Uptake is low in fat tissue. Uptake in the lung is also low but appears elevated on images without attenuation correction because of the low pulmonary density. Also the activity of the skin is overestimated on uncorrected images but may provide a convenient landmark for image interpretation. Image artefacts can result from technical defects, transmission image misalignment, patient motion or the pres-ence of an artefactual or normal hot spot on the image. They can frequently be prevented by careful attention to patient preparation. The patient should be fasting for a minimum of 4-6 h before the injection time to reduce serum insulin levels to near basal quantities. Water is permitted, however, to promote diuresis, and coffee might in fact increase fatty acid level and decrease myocardial uptake (Maisey, personal communication).
We recommend the i.v. cannular administration of between 100 and 400 Mbq of FDG in order to minimize the risk of extravasation and lymphatic migration. The injection site is chosen away from expected pathologic zones. As mentioned earlier, the patient should be in complete rest at the time of injection and during the waiting period. We routinely perform scanning 60-90 min after injection to increase tumoral to background contrast. This delay also allows better emptying of the urinary tract and voiding of the most concentrated urine before scanning. Imaging of the pelvis nevertheless presents significant problems, and forced diuresis (using 20 mg i.v. furosemide) is in our opinion necessary. The bladder should be emptied before the examination to eliminate the concentrated urine but we prefer to work with a bladder full of weakly concentrated urine whose spherical limits are clearly recognized rather than with an "empty" bladder whose activity cannot be precisely delimited. Often patients receiving diuretics require bladder catheterization to tolerate the duration of the scan. In these cases, we empty the bladder 10 min before scanning the pelvic area, then clamp the line and let the bladder fill until scanning. Typically scanning is started from the inguinal region upwards to minimize bladder activity. Artefacts from hot spots also result from the use of fittered backprojection algorithms for image reconstruction. They can be significantly reduced by the use of iterative reconstruction algorithms. The increase in computing power facilitates the use of these technique nowadays and they are recommended especially in the pelvis. Image interpretation can also be markedly facilitated by image fusion. The concomitant analysis of metabolic and structural information provides anatomical references frequently lacking in PET and a more precise estimation of lesion size, which is frequently a critical parameter in image interpretation (for instance to estimate the influence of the partial volume effect) [81] .
Clinical indications for FDG in oncology
Let us first examine the clinical indications for FDG imaging as they present along the course of the cancerous process [6, 62, [82] [83] [84] [85] [86] . We shall later discuss these indications in detail, tumour by tumour.
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Differential diagnosis
FDG PET has proved useful in the differential diagnosis of the solitary pulmonary nodule, the differentiation of pancreatic carcinoma versus mass-forming pancreatitis and the diagnosis of breast carcinoma in selected cases of mammography and/or biopsy failure (in particular in dense breasts and in implants). In other indications, such as the differential diagnosis of thyroid cancer in patients with cold nodules, PET may not be cost effective in comparison with a standard diagnostic strategy.
Initial (preoperative) staging of cancer
The importance of initial staging for optimal cancer management cannot be overemphasized. The success of therapy indeed depends on adequate staging. The role of diagnostic techniques in staging is, however, variable and depends on the efficacy of the screening methods for that cancer, on the propensity of the tumour for early metastases and on the role of surgery itself in staging. Initial staging by FDG has proven useful in lung cancer, melanoma and sarcoma. Initial staging in lymphoma is probably indicated as a baseline for therapy follow-up. FDG PET staging is also probably indicated in selected cases of other tumour types, especially when the tumour is at an advanced stage or when metastatic lesions are suspected by conventional imaging or suggested by high levels of tumour markers. Indeed, in these cases, FDG PET can provide sensitive whole-body screening. This is certainly the case for ovarian, head and neck and pancreatic carcinomas. Initial evaluation in colorectal cancer has been suggested, but results are inconclusive. Initial staging in breast carcinoma has been the subject of several studies. Although initial results were optimistic, recent reports in larger non-selected groups of patients have suggested that the sensitivity for the detection of axillary node metastases is around 75%. FDG PET can, however, depict internal mammary node metastases that are not routinely explored by the surgeon. At this stage, the role of PET in the staging and prognostic evaluation of breast carcinoma remains to be clarified.
Another indication related to initial staging is the search for the site of the primary tumour in patients with known metastases. According to Kole et al. [87] , the success rate of whole-body PET in this indication is approximately 25%.
Differentiation of scar and residual disease
Differentiation of scar and residual or recurrent disease is a frequent indication for PET and one of the first to be documented [88] . In 1988, Di Chiro et al. showed the value of FDG PET in distinguishing radiation necrosis from recurrent tumour in the brain [89, 90] . A similar differentiation has been reported to be useful in the lungs and in head and neck turnouts. Indeterminate pelvic masses on CT are frequent in the follow-up of colorectal cancer and require biopsy evaluation. Strauss et al. described the value of PET for distinguishing scar from recurrence [91] . The use of an iterative reconstruction technique to avoid bladder artefacts was essential in their success. FDG has also proven useful in the evaluation of residual masses after therapy for lymphoma. Gallium has previously been found useful in this indication but FDG, unlike gallium, does not require a baseline examination to verify that the tumour indeed accumulates the tracer.
Demonstration of suspected recurrences
Other cases of suspected recurrence occur when tumour markers increase or when the patient presents general or local clinical signs suggestive of turnout recurrence. Tumour markers are used routinely to follow up patients with colorectal, ovarian, breast, lung, thyroid or pancreatic cancers, etc., and in many cases conventional imaging fails to detect the recurrence because of its small size or its occurrence at a distance from the initial site. Several studies have concentrated on the value of PET for the detection of early recurrences in such cases, based on its high sensitivity and its whole-body capability. Indeed, whenever a recurrence is confirmed, the extent of recurrence becomes the next question as the clinician ponders the therapeutic options.
The impact of PET on management, avoiding unnecessary surgery, allowing more complete surgery or allowing surgery when it had seemed contra-indicated, forms the basis of its cost-effectiveness [92] .
Follow-up of therapy
FDG PET has been shown to be useful in evaluation of the early therapeutic response. FDG uptake can be markedly diminished or even completely suppressed after one or two cycles of chemotherapy, well before tumour mass can be shown to have decreased by conventional imaging. With the use of quantification, this technique has wide indications and is of interest for most cancers submitted to chemotherapy or radiotherapy (lymphoma, breast tumours, sarcoma, ovarian turnouts, germ cell tumours, head and neck carcinomas, lung cancer, colorectal cancer, hepatic metastases, etc.). Early determination of therapeutic resistance is also important to avoid the toxicity of an ineffective therapy and to allow selection of a new therapeutic regimen.
Prognostic value of FDG uptake
The prognostic value of FDG uptake has also been stressed by Alavi et al. [93] in cerebral tumours and by Reisser et al. [94] in head and neck tumours; tumours with higher FDG uptake appear more aggressive and to develop faster. The extent of metastatic involvement as depicted by PET and the evaluation of the therapeutic response also have prognostic significance.
Results in selected organs and cancer types
Lung tumours Differential diagnosis. Lung cancer is one of the most prevalent cancers in the industrialized world and a leading cause of cancer death in both men and women. Lung cancer may present as a solitary pulmonary nodule and be detected by conventional chest radiography. The incidence of these nodules is high: 130 000 new cases per year in the United States, or 52 cases per 100000 inhabitants. Despite the progress of imaging and in particular of computed tomography (CT), few criteria can reliably differentiate benign from malignant nodules [95] . The generally accepted criteria of benignity are:
1. Detection of a benign pattern of calcification (central, diffuse, popcorn) in the nodule 2. Stability of the nodule over the preceding 2 years 3. A very low probability of malignancy, based on age, particularly if exposure to tobacco smoke has been minimal
The clinician must therefore frequently choose between expectation, potentially dangerous in malignant lesions, and invasive diagnostic or therapeutic measures carrying high morbidity and also some mortality risk even when a benign lesion is present. It is currently estimated that 50%-60% of solitary pulmonary nodules are benign [96] . Yet despite current advances in morphological imaging the number of resected nodules proving benign remains high (20%-40% of the total), indicating that a substantial number of patients are needlessly exposed to peri-and postoperative complications [97] . Considerable experience is now available regarding the diagnostic value of FDG PET in solitary pulmonary nodules. Table 1 summarizes the main reported studies, including the date of publication, the number of patients studied, and sensitivity and specificity [70, 92, [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] . As can be seen, a high sensitivity has been achieved by all groups (average 96%). The specificity is also high but varies slightly more and probably depends on the local prevalence of the known causes of granulomatous disease responsible for false-positive cases (tuberculosis, histoplasmosis, aspergillosis, coccidiomycosis, blastomycosis, etc.).
We have prospectively studied 50 patients with undetermined solitary pulmonary nodules. Results of wholebody PET (neck to mid abdomen) were correlated to the surgical or transthoracic needle aspiration biopsy of the lesion (Fig. 2) . Thirty-three pulmonary cancers were correctly identified while 15 of 17 benign nodules were 
Fig. 2. Malignant solitary pulmonary nodule (adenosquamous cell carcinoma).
Chest X-ray and CT showed an unspecified 1.7-cm solitary pulmonary nodule recognized. There were two false-positives (one case of active tuberculosis and one case of pseudotumoral anthracosilicosis with partial necrosis and perinecrotic inflammation). At present, our positive predictive value is 94% while our negative predictive value is 100% [106] [107] [108] . Dewan et al. have compared the use of PET with a diagnostic strategy based on CT and transthoracic fineneedle aspiration (TTNA) biopsy [105] . In 35 lung lesions PET correctly identified all 26 malignant lesions as well as seven of the nine benign lung lesions, but produced two false-positive readings. In contrast, TTNA was positive for malignancy in 21 lung lesions (five false-negative) but did not result in false-positive findings. The overall predictive accuracy was 94% for PET and 86% for TTNA but the latter resulted in a pneumothorax in 16 patients while nine patients (26%) required chest tube aspiration. This complication rate appears fairly typical as compared with other reports [109] .
Use of FDG PET for differentiation of solitary pulmonary nodules could lead to significant savings in addition to reducing the number of complications during management [92, 105] .
Application of the quantitative technique to the diagnosis of solitary pulmonary nodules has been evaluated.
It appears effective and certainly increases the objectivity of analysis but it does not appear to significantly improve the diagnosis as compared to visual analysis [64, 70] . Reproducibility is maximal for SUV (SUV related to lean-body mass corrected for blood glucose concentration) and for K i (slope of the graphical analysis as defined by Patlak). Parameters derived from compartmental modelling have been less reproducible [74] .
Preoperative staging. In patients with known lung carcinoma, the results of staging both within and outside the thorax are the key in determining the operability. Demonstration of a unilateral hilar adenopathy is not a contra-indication to surgery if the nodes can be resected with the primary tumour. By contrast, extensive mediastinal involvement, contralateral lymph node involvement, and pleural or distant metastases should contra-indicate surgery due to the surgical morbidity and the poor prognosis.
Several studies have evaluated the role of FDG PET for staging lung carcinoma. These studies must be separated into two groups, Some investigators have used focal techniques and have concentrated on hilar and mediastinal lymph node staging, while others have used whole-body techniques and have evaluated extrathoracic (Table 2 ) [49, [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] . The reported sensitivity for lymph node staging in non-small cell lung cancer varies from 82% to 100% and the specificity from 73% to 100%. We have prospectively studied 50 patients prior to thoracotomy [119, 120] . The prevalence of hilar or mediastinal lymph node involvement was 58%. We have obtained values of 85% (sensitivity) and 81% (specificity) with a positive predictive value (PPV) of 85% and a negative predictive value (NPV) of 81%; by comparison, these four figures with CT were 64%, 68%, 67% and 65% respectively. It is interesting to note that CT both underestimated and overestimated the extent of disease, so that in comparison PET would have contributed both to cancellation and to confirmation of surgery as a therapeutic modality. PET in this indication appears to supply information currently only partly provided by mediastinoscopy. Given the high sensitivity of PET for mediastinal staging, a negative result should allow one to proceed to surgery without mediastinoscopy. Considering the 15%-20% false-positive rate however, a confirmatory mediastinoscopy remains indicated in patients with less specific uptake patterns (mild uptake, moderate uptake and nodal enlargement, or discordant PET and CT results). Whole-body FDG PET also contributes to significant management changes as first assessed by Lewis et al. in 34 patients [115] . In this study, unsuspected malignant metastatic lesions were recognized in ten patients (12 extrathoracic and eight thoracic sites). Management changes were noted in 14 patients. Six (+2) patients were classified as unsuitable for surgery while eight patients with equivocal findings were found to have single PET lesions. A frequent location of suspected metastases are the adrenals, where CT detects many non-specific abnormalities. PET can confirm or exclude such metastases effectively [121] . Our own results confirm the data of Lewis [122] . We have studied 61 patients by conventional imaging and whole-body PET for staging of nonsmall cell lung carcinoma. When CT or PET study suggested metastatic disease, confirmation was obtained by biopsy or clinical or radiological follow-up. As compared to CT, PET correctly changed the N stage in 13 patients (21%): it increased the stage in six patients and decreased it in seven. Presence of metastatic lesions (n=28) was confirmed in 19 patients: eight homolateral or contralateral lung lesions, six hepatic lesions, four adrenal lesions, five bone lesions, one pleural lesion, three lymph node metastases and one skin lesion. All showed intense FDG uptake on PET. In contrast to CT, PET correctly identified unsuspected extrathoracic lesions at ten distant sites in five patients. There were no known falsenegative distant PET findings. However, there were three false-positive distant PET findings (versus seven with conventional imaging) corresponding to moderate uptake in inflammatory lymph nodes (two axillary and one lung). We believe that the whole-body PET technique can improve the diagnostic accuracy in the staging of non-small cell lung cancer.
Valk et al. [117] , in a recently reported study concerning subsets of 76 and 99 patients, also noted that PET correctly changed the nodal stage as determined by CT in 18 staging evaluations (24%), increasing the stage in eight patients and decreasing it in 11, including one false-negative. PET changed the metastasis stage in 30 patients: previously unsuspected distant metastases were demonstrated in 11 patients while normal PET findings were obtained at distant sites of CT abnormalities in 19 patients (one false-negative).
Detection of cerebral metastases. The detection of cerebral metastases is also possible using FDG PET but a dedicated cerebral PET sequence is probably needed. Larcos and Maisey [123] have tested the efficacy of a supplementary 10-rain brain sequence in patients with various malignancies. Cerebral metastases were reported in four patients (1.5%), only two of which were unsuspected prior to the PET scan. The authors conclude that "routine" screening for cerebral metastases in patients with suspected malignancy may not be clinically useful.
Demonstration of recurrences; follow-up of therapy. Experience is also available regarding the use of PET to assess lung tumour response to therapy and in the detection of recurrences after successful initial therapy. Abe et al. [124] demonstrated that patients judged to have a clinically complete response to radiotherapy or chemo-therapy had negative PET results while results remained positive in patients with a partial response. Knopp [124, 125] . Others have also reported a high diagnostic accuracy of FDG PET in the detection of tumour recurrence [113, [126] [127] [128] [129] [130] .
PET in pIeural disease. In a related subject we have also shown the value of PET in the assessment of patients with malignant or non-malignant pleural effusion [ 131 ] . We have investigated the utility of FDG PET for the aetiological diagnosis of pleural disease in 25 patients. Sixteen had malignant pleural disease (three primary mesotheliomas and 13 cases of metastatic pleural involvement) while nine had non-malignant pleural disease (three benign tumours and six pleural infective processes). All three mesotheliomas and 11 cases of metastatic involvement displayed intense FDG uptake. Two patients with metastases and two with infection had moderate uptake. Seven patients with benign lesions had no uptake. PET appears useful to reduce the number of both open pleural biopsies and limited thoracotomies for benign pleural disease. Patients without FDG uptake appear unlikely to have cancer. Patients with mild uptake require biopsy, potentially directed by PET data, for differential diagnosis. In patients with intense uptake, the PET data can also be used for biopsy guidance for histological confirmation when needed.
Similar data have been reported by Lowe et al. [132] in 23 patients with biopsy-proven diagnosis. Six patients had benign pleural abnormalities, including four with SUR values below 2.5. Of 17 patients with malignant disease, 15 had SUV values above 2.5. Two patients with active infection in the pleural space also had increased FDG uptake.
The role of FDG PET in patients with small cell lung carcinoma has only rarely been discussed. FDG nevertheless appears to have some potential role in differentiating limited disease from extensive disease as well as in the follow-up of therapy [125] .
In summary, results in lung cancer provide evidence for many different clinical indications for FDG PET at the various stages of the disease, including differential diagnosis of solitary nodules, initial preoperative staging of the nodal extent of non-small cell lung cancer, detection of unsuspected metastases, differentiation or demonstration of suspected recurrence, and therapeutic follow-up [133] [134] [135] [136] .
Tumours of the gastro-intestinal tract
Colorectal carcinoma
Colorectal carcinoma is a frequent tumour and presents successive diagnostic problems at the time of initial di-agnosis, staging and assessment of recurrence following therapy.
About 70% of patients have resectable tumours initially but recurrences do occur in one-third of patients, most commonly during the first 2 years after operation. Such recurrences can be locoregional, but more often distant or generalized metastases occur and currently only about one-quarter of patients with recurrences can be cured by re-intervention [ 137] .
The techniques available for the staging and assessment of potential recurrences lack sensitivity and precision and frequently result in diagnostic and therapeutic delays. Tumour markers, although useful, have only a 59% sensitivity and an 84% specificity for recun'ences [138] . Barium enema detects local recurrence but is insensitive (49%) for overall recurrence detection [139] . Similar results are reported for colonoscopy. CT is useful for liver metastases but not nodal involvement [140] . Numerous patients with negative CT have a non-resectable tumour at the time of surgery.
FDG is avidly concentrated in colorectal carcinoma and current studies indicate an important role of PET in the evaluation of this cancer. The first report dates back to 1982, when liver metastases of colorectal cancer were visualized in a feasibility study of FDG and PET at Brookhaven National Laboratory [141] . Since then a number of studies have been published, confirming the value of the technique.
Preoperative detection and staging. Detection of the primary tumour at the time of diagnosis appears possible but insufficient data exist to suggest that PET might play a role in staging at that time although it has an accuracy superior to that of CT [142, 143] (PPV is 93% and NPV 50% for FDG PET versus 100% and 27%, respectively, for CT) [142] . Rather, the clinical and economic impact of PET appears more clearly in the evaluation of postoperative recurrence.
Detection of locoregional recurrences. Patients with presacral masses and suspected local recurrences were first studied by the group from the German Cancer Research Centre in Heidelberg. In several successive studies, these investigators [91, 144] demonstrated the value of PET in differentiating scar tissue and tumour in this setting, a finding later confirmed by Ito et al. and Schiepers et al. [145, 146] (Table 3) . In contrast, when a presacral mass is identified on CT, it is very difficult to diagnose its origin: scar, fibrotic tissue or tumoral recurrence. Biopsy is needed but is only useful when positive as false-negative results are frequent and due to unavoidable sampling errors [147] . Transrectal ultrasonography (US) can demonstrate the depth of involvement of distal lesions as well as the presence of pararectal adenopathies. PET in this indication appears very useful and clearly superior to CT (95% diagnostic sensitivity) but it has not been systematically compared with rectal US [91, 146] . It has the advantage, however, that the pelvic study is only one part of the whole-body survey.
Staging of patients with suspected or demonstrated recurrences.
Results demonstrating the value of FDG PET in the identification of patients with isolated resectable lesions and in distinguishing them from patients with disseminated metastases have came from the group in Leuven, using the PET whole-body technique. Schiepers et al. evaluated 76 patients presenting with or suspected of having recurrent local or distant colorectal cancer [146] . The accuracy of PET for focal disease was 95%, showing it to be superior to CT of the pelvis (65%). The accuracy of PET for liver metastases (98%) compared favourably with that of CT or US (93%). Unexpected extrahepatic metastases were detected in 14 locations in ten patients. In a previous study on 35 patients, Beets et al. from the same group, evaluated the clinical impact of PET on management [148] . Sixteen patients presented with "resectable" metastases, eight with resectable pelvic recurrences, eight with a presacral mass of uncertain nature and three with an isolated increase in the carcinoembryonic antigen (CEA) level. PET affected the management decision in 7 of the 16 patients with metastatic disease; it detected additional lesions in two patients with pelvic recurrences as well as the site of the disease in two of the patients with an increased CEA level. Overall, PET affected management in 14 of the 35 patients. Falk et al. [142] , Gupta et al. [149, 150] , Pounds et al. [151] and Bohdiewicz et al. [152] , as well as data from our own group [154] , have also stressed the value of whole-body PET for staging recurrent disease in colorectal carcinoma (Table 4) .
A multicentre study organized by the Institute for Clinical PET has examined the issue of cost-effectiveness in colorectal carcinoma based on a survey of 14 PET centres and a review of 267 colorectal cancer patient records [155] . This preliminary report suggests a large potential saving based on the elimination of exploratory laparotomies and on a reduction (from 20% to 10%) in the number of resections with curative intent (Fig. 3) .
Evaluation of therapy. In 1991, Haberkorn et al. [156] evaluated patients with known recurrent disease prior to and after radiotherapy. FDG tissue levels tended to fall after therapy but changes in uptake parameters were not able to accurately predict therapeutic responses in individual patients. The authors suggested the potential role of radiation injury and of the inflammatory reaction in these results. Inflammation and metabolically active residual turnout tissue cannot be distinguished early after therapy.
In another report in 21 irradiated patients, Engenbart et al. [157] found that residual FDG uptake indicated the presence of residual tumour and a poor therapeutic response. PET was the earliest indicator of local relapse. The use of 18F-5-fluorouracil in the therapeutic evaluation of patients with colorectal cancer is beyond the scope of this review.
Pancreatic carcinoma
Among gastro-intestinal cancers, pancreatic carcinoma has the worst prognosis. This may result from the difficulties encountered in the diagnosis of this cancer, which manifests only with non-specific clinical symptoms and with indirect signs on routine structural imaging (CT or US) [158, 159] . Many nuclear medicine techniques have been proposed in the past to visualize the pancreas but studies performed with amino acids or blood flow tracers lack specificity for tumour visualization. Indeed, these tracers also accumulate in the normal pancreas and cancerous lesions usually appear as cold spots. Lesions of other aetiologies, however, also correspond to cold spots and this finding is not specific [160] [161] [162] .
Several groups, predominantly from Japan and Germany, have evaluated the role of FDG PET in the differentiation of pancreatic adenocarcinoma from benign chronic pancreatitis and mass-forming pancreatitis [163] [164] [165] [166] [167] [168] [169] . Results indicate a sensitivity of ca. 94% with a specificity varying from 78% to 90% (Table 5 ). The optimal SUV cut-off varies between studies but is rather low (ca. 2) as glucose uptake in the normal pancreas is also low. On rare occasions, uptake in the site of pancreatitis is markedly elevated; generally, however, it is only slightly higher than in normal controls. Visual criteria use discrete focal elevated uptake as evidence for cancer, while diffuse or background level activity is taken as evidence for chronic pancreatitis or normal tissue. Bares et al. [163] first commented on the importance of adequate blood glucose control for optimal FDG uptake by the tumour. Indeed, glucose competes with FDG for transport and a high level of plasma glucose could inhibit FDG uptake within the tumour. Bares suggested this competition to be a possib][e cause of false-negative results, but the four patients with false-negative findings reported by Stollfuss did not have diabetes or elevated glucose levels [163, 168] . Evidence of metastatic extension of pancreatic carcinoma, lymph node involvement or liver metastases can be appreciated on PET images. However, no systematic study has yet been reported on the value of PET in this indication.
Gastric and oesophageal tumours
Little information is available on the role of FDG PET in the evaluation of gastric and oesophageal tumours [150, 170, 171] . In our limited experience, the ability of FDG PET to visualize the primary tumour is excellent. Its value in assessing the extent of the disease, progression to contiguous structures, nodal involvement or hepatic metastases has not been systematically examined yet, to our knowledge.
Liver metastases and hepatomas
Cancers of the digestive tract, colorectal carcinoma, pancreatic cancer, gastric or oesophageal tumours and cancer of the biliary tract demonstrate a high prevalence of haematogenous liver metastases, as do breast cancer, ovarian cancer, lung cancer, etc. Current diagnostic modalities (mainly US and CT) have suboptimal accuracy and many studies are reported as inconclusive [172] . Bi- The image contrast between the uptake within liver metastases and that in normal tissue increases over time as a result of the high level of glucose-6-phosphatase activity within normal liver tissue. This results in decreased 18F radioactivity in normal tissue over time and in greater visibility of the lesion [158, 178] . It is therefore appropriate to perform FDG liver imaging in patients with suspected liver metastases approximately 90 min after FDG injection. Attenuation correction remains possible in these cases if the transmission studies are performed after the emission study, as is nowadays possible, or if the attenuation correction is calculated using the body contour rather than based on transmission data. In the latter case, imaging of the patient with his arms out of the scanner is essential for adequate performance.
While delayed imaging improves contrast between liver metastases and normal liver, this is probably not the case in at least some patients with hepatoma. Indeed, while a large fraction of hepatomas are well imaged by FDG PET as hot spots relative to the liver, up to half of the tumours cannot be detected as regions of increased tracer uptake compared with normal liver [34, [179] [180] [181] [182] . This latter patient group appears to retain a high dephosphorylation rate within the tumour cells. Enomoto et al. [180] have suggested that kinetic modelling could be used to better characterize hepatoma. In 35 patients with liver lesions confirmed by surgery, they analysed tracer kinetics using the Sokoloff model [32] . k 3 was correlated with tumour hexokinase content and the presence of cancer. Patients with hepatoma and a high k4/k 3 ratio appeared to have the best survival.
Lymphomas
Several reports have shown the feasibility of imaging lymphomas using FDG [183] [184] [185] [186] [187] [188] [189] [190] . This approach is of particular interest as metabolic imaging does not face the difficulties of structural imaging modalities in defining the presence and extent of lymphomatous turnouts. CT and MRI require perturbation (e.g. space occupation) or enlargement (e.g. nodal) of anatomical structure to suggest tumour, and abnormal findings lack specificity [185] .
Limitations of current structural imaging techniques appear even more striking subsequent to therapy [184, 191] . Changes in anatomical indicators are slow and may lag behind reduction in the number of viable tumour cells. Indeed, it appears that fibrosis develops as a result of tumour necrosis and initially enlarged tumour sites may remain permanently enlarged after effective sterilization of the tumour. FDG appears particularly useful for the assessment of therapy in patients with lymphomas as changes in the metabolic stage of the tumour appear to reflect more closely viability of the remaining tumour cell mass than tumour volume [189, 192, 193] .
Initial staging. FDG imaging in lymphoma was first reported by Paul [183] . He compared FDG with gallium-67 using planar imaging in five patients with non-Hodgkin's lymphoma and detected abnormalities in four of the patients with FDG as compared with two of them using gallium.
Okada et al. reported on 21 and then 23 patients with lymphoma of the head and neck regions [36, 187] . Abnormal PET studies were reported in all patients, while gallium uptake was abnormal in 20 of 21 patients. Low-grade lymphomas appeared to have less FDG uptake than higher grade lymphomas as a good correlation was obtained between FDG uptake and biopsy-obtained estimates of tumour proliferative rate. It has also been suggested that increased FDG uptake is associated with a less favourable prognosis for the lymphoma patient [194] .
Leskinen-Kallio et al. [195] also observed that increased FDG uptake was proportional to the histological Based on studies in 14 patients, the authors suggested that 11C-methionine might be superior to FDG in detecting lymphomas but that FDG was better at distinguishing tumonr grade. Newman et al. [185] compared FDG PET and CT in 16 patients with mixed lymphoma cases. PET (not using the whole-body technique) identified 54 abnormalities in 13 patients compared with 49 by CT. Subsequent studies remained normal in the three patients with normal PET scans. Rodriguez et al. [35] also report on the role of PET in predicting malignancy grade. These limited results suggest the value of FDG for the detection of even low-grade tumours.
Several other abstracts support the effectiveness of FDG PET in lymphomas [193, 196, 197] . PET usually demonstrates more lesions than CT and this may result in patient upstaging (three cases among 26 patients with Hodgkin's disease [198] ) and in changes in patient management.
We have studied 42 patients with histologically proven lymphomas [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] . Twenty patients had aggressive non-Hodgkin's lymphoma (NHL), 13 low-grade NHL and 9 Hodgkin's disease (HD). Thirty patients were evaluated at initial presentation while 12 underwent PET for disease recurrence. Evaluation of disease extension was performed by PET and compared with clinical evaluation (presence of lymph nodes with a minimal diameter of 10 mm or more in the cervical, axillary and inguinal regions), with CT (standard size criteria of 1.5 cm used to define pathology) and with biopsy when available. PET detected more lesions than clinical examination and/or CT in patients with aggressive NHL or HD (9 of 29 patients had more PET sites than clinical sites; 3 of 29 patients had more PET sites than CT sites). Results were different in patients with low-grade NHL: Concordant results were observed in 9/14 patients by clinical examination and in 7/13 patients by CT. More sites were detected by PET than by clinical examination in two patients and more were detected by PET than by CT in one patient, while more sites were detected by clinical examination in three patients and by CT in five patients. These results differ from other reports concerning low-grade NHL [185, 186] . One possible reason is that other reports have concentrated on a single area for comparison while this study involved whole-body scans. As the uptake in low-grade NHL is lower than in highgrade tumour, the sensitivity of the whole-body technique with limited scanning time may be insufficient to detect all lesions.
Additionally we have found that PET is valuable for the detection of splenic involvement and digestive tract infiltration (three of four cases were detected). By contrast, PET does not appear useful for the detection of bone marrow infiltration as it cannot differentiate bone marrow involvement from non-specific bone marrow stimulation or from growth factor stimulation.
Follow-up of therapy and detection of recurrences and of residual disease.
We have also assessed the role of FDG PET imaging in the evaluation of therapy (Fig. 4) . Our results concern 55 cases studied for early treatment evaluation (19 patients), end of therapy assessment (18 patients) and detection of recurrences (25 patients). Early response to therapy (two to three chemotherapy cycles) defines a subgroup of patients with good prognosis (eight of nine patients have remained in remission 8 months after the end of therapy) while patients with re-sidual FDG uptake have a poor prognosis (four deaths and one case of residual disease among ten patients). FDG PET also appears useful in differentiating scar from residual disease in patients with residual masses and in detecting early recurrences: PET was positive in all cases of clinical recurrence (11 patients) while it detected lesions in three patients with clinical remission [ 
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These results need to be confirmed in larger patient groups and with longer follow-up but it already appears that FDG could play an essential role in the follow-up of lymphoma therapy to confirm the therapeutic choice and good prognosis, or, on the contrary, to detect therapeutic resistance at an early stage [201, 202] . Potentially toxic regimens could be stopped early in the latter patients and replaced by an alternative regimen. PET could also be used to select responders for highly toxic or very expensive treatment and enhance both the cost-effectiveness of treatment and the quality of life in these patients.
Head and neck carcinomas
Head and neck carcinomas are associated with the abuse of alcohol and/or tobacco and their frequency is increasing. They take their origin in the superior alimentary and respiratory tracts and mainly comprise squamous cell carcinoma (90%). Other lesions take their origin in glandular tissues (mainly the salivary glands) or in lymph nodes. Head and neck carcinomas have high glycolytic activity and their successful demonstration with FDG was reported in the late 1980s with the use of a specially collimated gamma camera [202] . Use of l lC-methionine has also been proposed in this indication [203, 204] .
Initial diagnosis and staging of head and neck carcinomas is based on clinical examination. This is usually quite successful as most tumours are reasonably accessible to observation and palpation by the head and neck specialist. The clinical examination is usually completed by CT or MRI and by biopsy. Palpation has, however, been reported to be superior to structural imaging for lymph node involvement as the latter is strictly based upon the size of the lymph node while palpation assesses the node structure and induration [205] .
PET metabolic criteria offer some advantages over anatomical imaging. They can detect superficial or submucosal primary tumour infiltration without adjacent tissue deformation. They can also indicate uptake and involvement of normal size lymph nodes while showing no involvement in some enlarged reactive lymph nodes. Evaluation of the accuracy of FDG PET in the diagnosis of the primary tumour has been performed to validate its potential in this type of tumour rather than to support its clinical use in this indication [206] [207] [208] [209] . Minn et al. were able to image 13/13 cancers using FDG [202] . Bailet et al. [210] identified 16/16 primary lesions using PET, including one lesion not well delineated by anatomical imaging (superficial tumour involving the anterior tongue). These tumours have a high tumoral to normal metabolism ratio as reported in a concomitant paper from the same group [40, 211] . McGuirt et al. [212] studied 25 patients with laryngeal carcinoma before definitive therapy. PET identified the primary tumour in 22 cases. There were one false-negative and two equivocal lesions, all in the supraglottic region. McGuirt et al. [213] also reported on the identification of benign versus malignant parotid masses. PET identified all 26 lesions and all 12 malignant lesions but made the correct categorization in only 69% of cases. Indeed, six benign lesions (Warthin's tumours, pleomorphic adenomas and a toxoplasmosis adenopathy) presented falsely positive uptake [214] .
In summary, PET is potentially useful in selected indications in patients with primary ENT turnouts, for instance to direct the site of biopsy, but cannot be proven cost-effective in this setting.
Definition of lymph node extension in patients with ENT tumour is potentially a more useful indication as lymph node metastases are frequent in the evolution of these cancers and represent the most determinant prognostic factor [215, 216] . Sixty percent of patients have one or more palpable adenopathies at the time of diagnosis while 40% have lymph node metastases. The average 5-year survival is >50% in the absence but only around 30% in the presence of lymph node metastases [217] . Presence or absence of invaded nodes also determines the type of therapy [218, 219] . In particular, the presence of contralateral disease in a patient eliminates surgery as a treatment option.
Ballet et al. [220] evaluated 203 lymph nodes from eight neck dissection specimens; 17 were positive for malignancy. PET accurately diagnosed 12 (71%) of these positive nodes, as against ten diagnosed by anatomical imaging. PET was false-positive in three reactive nodes. McGuirt et al. [212] correlated the neck nodal status in 27 specimens from 17 patients. PET agreed with pathology in 22 cases (81%), with three false-positives and two equivocal specimens. In a separate study, the same authors reported on 49 patients of whom 45 underwent neck dissection, allowing corroboration of clinical and imaging results with histopathological data. PET and CT yielded similar results (82% and 84% accuracy) and were superior to clinical assessment (71% accuracy) [206] .
In our experience in 19 patients with surgical and histopathological verification, PET detected all primary tumours [217] . PET correctly interpreted the absence of metastatic lymph nodes in 11/14 patients but there were three false-positive reactive nodes. PET detected one involved contralateral lymph node in one patient that was not detected by CT or clinical examination. Finally, PET missed two cases of microscopic nodal foci also undetected by CT and clinical examination.
Definition of residual or recurrent disease after radiotherapy or surgery presents more of a challenge for the clinical examination as well as for anatomical imaging. The fascial planes can be distorted or destroyed by postsurgical scarring or post-irradiation fibrosis and normal anatomical structures may be unidentifiable. FDG PET appears ideally suited in these indications, as suggested by initial reports [221, 222] (Fig. 5) .
Greven et al. [223] reported on 18 patients studied 4 months after radiotherapy. Eleven patients had a normal PET scan at the primary site and none had subsequent recurrence. Seven had abnormal FDG uptake and six of these had biopsy-proven recurrence. Fifteen patients had normal PET at the nodal site and none had recurrences while three patients had abnormal PET with evidence of biopsy-confirmed nodal recurrences in two. Similarly, Ballet et al. [220] compared PET and MRI in ten patients with recurrent tumours 4 months to 4 years after radiotherapy. PET determined recurrence in all patients while MRI was negative or inconclusive and clinical examination was frequently non-specific. A comparative study of FDG SPET and thallium was reported by Mukherji et al. [224] .
FDG PET has also been used to monitor tumour response to various chemotherapy or radiotherapeutic regimens. According to Chaiken etal. [225] , elevated or rising FDG PET activity after radiation therapy was indicative of persistent or recurrent disease in 89% of cases (8/9) while a significant decrease in activity was observed in patients in whom local control was achieved. Greven etal. [223, 226] , however, did not believe that early PET scan (1 month) accurately reflects the status of disease and recommended a minimum delay of 4 months. These studies extended previous work by Minn et al. [202] and Haberkorn etal. [227] , who documented a significant decrement in uptake ratio after irradiation among radioresponsive but not radioresistant tumours. Similarly, tumours appear more sensitive to chemotherapy than lymph nodes [228] .
Prognosis. As suggested by Reisser et al. in 50 patients, FDG uptake before therapy can predict prognosis [94, 229] . Patients with an SUV above 3-4 (300%-400%) had a less favourable prognosis than patients with a lower SUV value.
Breast cancer
Breast cancer is the most frequent malignant tumour in women of Western countries [230] . The most frequent form is an adenocarcinoma of the endothelial cells of the galactophorous ducts. It is primarily localized in the external upper quadrant (50%), in the internal upper quadrant or in the central regions. Breast cancer is in many cases a systemic disease. Indeed, disease recurrence is metastatic rather than locoregional in nine of every ten cases. Metastases appear early in the course of the disease while the tumour growth rate is slow (doubling time: 1-3 months; a tumour reaches 1 cm after 5 years and 2 cm after 10 years) [231] [232] [233] .
Local extension is along the galactophorous ducts to the nipple and the remaining gland, skin and deep tissues. Breast carcinoma is frequently multicentric (30%) or bilateral (7%). Locoregional extension is via the lymphatic system and carries important prognostic value. Nodal metastasis is found in 60% of patients at the time of diagnosis and the 5-year recunence-free survival is 75%, 45% and 20% with involvement of no, one to three, and more than three axillary nodes, respectively. Mortality is also clearly related to the presence or absence of metastasis [234] . The primary lymph pathway is by contiguity along the external mammary pedicle to the first, second and third axillary groups from the external superior quadrant. The central and internal quadrants also carry lymph to the internal mammary node groups (between the second and third intercostal spaces). From these, extension to the sub-and supraclavicular groups, upper mediastinal groups and contralateral axillary groups is possible. Systemic metastatic extension is haematogenous and primarily affects the axial skeleton, the liver, the lung and the pleura. The brain, ovaries, adrenals and skin are less frequently involved. Several other prognostic indicators have been recognized beyond nodal extension: primarily the size of the tumour, the presence or absence of local inflammatory signs, the presence or absence of hormonal receptors [235] [236] [237] (progesterone receptors have greater prognostic value than oestrogen receptors) and the age of the patient (women under 35 years have twice the rate of axillary involvement as older women). The histopathological classification based on the degree of differentiation (SBR grades I-III) also carries prognostic information [238] , as do more recently developed oncogene-related markers [239] .
Diagnosis. Initial therapy is decided upon based on the results of staging and of the prognostic evaluation. The role of PET and in particular of FDG PET in the diagnosis and management of breast carcinoma has been the subject of several studies [240] [241] [242] [243] [244] . Several groups have reported a high degree of success in detecting the primary tumour. Although the first feasibility studies included only small numbers of patients with large tumours, larger more representative series have now been reported [245] [246] [247] [248] . Using a whole-body imaging technique, Hoh et al. [83] detected 15/17 primary breast carcinomas. Nieweg et al. [249, 250] identified 10/11 primary lesions. Adler et al. [251, 252] , in a prospective study, recognized 26/27 malignant lesions. While other studies are forthcoming (some of them are already available in abstract form) that will confirm the high sensitivity of PET for the detection of the primary lesion, it should be noted that most studies have evaluated breast masses of more than 1.0 cm in diameter and that the sensitivity of the method for definition of small cancers remains to be established [81, 253] . Also the method's specificity has not been fully determined in a large number of benign lesions. Therefore current results must still be considered preliminary. The need for a new technique in the primary diagnosis of breast tumours must be weighed against the sensitivity and cost of current modalities. There appears to be little space for FDG PET, given the role of mammographic screening and confirmation by needle or surgical biopsies. One potential area of application, however, is in patients with silicone implant augmentation mammoplasties, as reported by Wahl [254] . Use in patients with dense breasts or in patients with unsuccessful needle biopsy has also been suggested.
Nodal extension. Evaluation of axillary nodal extension could prove a more practical indication for FDG PET. Indeed, it could potentially replace axillary lymph node dissection (ALND). ALND is currently performed for its prognostic value only, yet carries significant morbidity and cost [234, 255, 256] . Complications include postoperative seroma formation, arm oedema, breast oedema, nerve injuries and shoulder dysfunction. ALND can significantly prolong hospitalization, anaesthesia and postoperative care or be a separate procedure when associated with breast conservation therapy.
The current incidence of patients with positive node dissection among those receiving partial mastectomies has dropped to 25% in some reports (probably due to earlier detection). As calculated in an ICP report, a sensitivity and specificity of 90% and 95% respectively would have an NPV of 97% and spare 33 patients the morbidity of ALND at a cost of missing one patient with lymph node involvement [257] . More conservative estimates of sensitivity and specificity (75% and 90% respectively) would result in an NPV of 92% and spare 25 patients the morbidity of ALND at the cost of missing two patients with lymph node involvement. As suggested by the authors of the ICP report, even this higher error rate may be justifiable given the limited improvement in survival that would be expected from chemotherapy [257] .
Initial results of PET in patients with advanced breast carcinoma demonstrated a high rate of detection of lymph node metastases. Results in subsequent studies have varied from 67% [83] to 90% [251] but the number of patients studied remains low and results appear to vary in part with the technique used (sensitivity is potentially higher using an attenuation-corrected static scan than with a whole-body non-attenuated technique) (Table 7). Recent results and our own experience suggest a 75%-80% sensitivity with good specificity (96%) [253] . If larger studies in stage I or II breast cancer patients confirm both the sensitivity and the specificity of PET and a low incidence of lymph node metastases (<30%) to yield a high NPV (>90% or preferably >95%), PET could replace ALND in these patients. As mentioned earlier, PET also has the potential to detect internal mammary lymph node metastases and this should be a significant advantage in patients with central or internal quadrant tumours. Unfortunately, no data have yet been reported on the clinical impact of this feature. Metastatic staging. PET also has the potential to detect distant metastases, e.g. in the liver, skeleton or more distant nodal chains. Such metastases will radically alter patients' management. In this context the use of wholebody PET could potentially replace the need to perform a conventional metastatic survey including CT, US and conventional skeletal scintigraphy [258] . Available data point to the value of PET in this indication but it has not yet been tested in specific patient groups, such as patients with stage III breast cancer at the time of initial diagnosis, or later on in the disease, eog. in patients with suspected recurrences [246, 249, 250, 259] .
Therapy follow-up. Finally, a number of reports have assessed the role of FDG and PET in assessing response to breast cancer therapy (Fig. 6) . Wahl et al. studied 11 women with newly diagnosed primary breast cancer larger than 3 cm in diameter and undergoing a chemohormonotherapy programme [59] . These patients had one baseline and four follow-up quantitative PET scans to test the feasibility of non-invasive metabolic therapy monitoring. Tumour uptake decreased rapidly in eight patients with partial or complete response while it did not change in non-responders. The metabolic response preceded decrease in tumour size. Furthermore, effective chemotherapy, when repeated, leads to diminution of glucose uptake levels to basal values while FDG uptake increases in patients receiving inefficient therapy. Reports from Nieweg et al. [250] , Chaiken et al. [225] and Jansson et al. [260] also suggest a role for PET in the follow-up of therapy.
We have used FDG PET in ten patients considered for bone marrow transplant. Evaluation of the disease extent before chemotherapy and of the initial results after two to three therapy courses has helped us to identify responders, who were submitted to transplant after full therapy, and non-responders, in whom the approach was discontinued to prevent further unnecessary bone marrow toxicity. PET evaluation of early therapy response could also be used to individualize drug selection in difficult cases.
Melanoma
Melanoma is a cutaneous malignancy whose frequency is increasing. It has a high mortality related to its propensity for early nodal metastasis and hematogenous visceral spread. Between 20% and 40% of patients with clinically localized lesions have nodal metastases found at surgery. Although sentinel node biopsy offers promise in the detection of such patients with minimally invasive surgery [261] , a technique to non-invasively detect the presence of involved nodes would obviously be of value. Also in treated patients, detection of recurrences or of metastases is made difficult by the wide range of potential hematogenous spread of the tumour. This requires regular chest, abdomen, pelvis and brain CT or MRI, as well as confirmatory procedures in cases of indeterminate or suspicious results [262] .
Staging. In animals, melanoma is one of the tumours with the highest glycolytic metabolism and FDG uptake [263] . Initial evaluation confirms the high sensitivity of FDG PET in detecting melanoma lesions. Gritters et al. performed limited area scanning in 12 patients in regions of the body having or suspected to contain malignant melanoma on the basis of physical examination and prior imaging data [264] . In superficial lymph nodes, PET correctly identified 7/7 metastastic lymph nodes (including three normal size lymph nodes) and correctly predicted the absence of tumours in 6/6 lymph nodes (accuracy 100%). The sensitivity of PET was also very high for intra-abdominal visceral metastases (15/15) ranging in size from 0.5 to 8.0 cm. Five of these lesions were only seen on CT retrospectively or several months later. PET, however, was much less successful in detecting pulmonary metastases (4 of 27 lesions in four patients) but most of the lesions were under 1 cm in size.
Steinert et al. [265a, 265b] reported on the role of whole-body PET with FDG in staging malignant melanoma in 33 patients. Twenty-three had known metastatic disease while ten had a newly diagnosed melanoma with a high risk of metastases (Breslow thickness >1.5 mm). Of 55 evaluated lesions, 40 proved to be metastatic. PET correctly identified 37 sites but missed three small (<3 mm) cutaneous metastases. It depicted metastases in six patients and excluded malignancy in ten suspicious sites. Specificity evaluated in ten enlarged benign lymph nodes and three inflammatory lesions was 100% using marked uptake criteria or 77% using mild uptake criteria (concomitant sensitivity varied from 73% to 92%). In this study PET detected three of 3 thoracic lymph nodes, albeit with mild intensity only in two cases.
Other studies and abstracts confirm the high sensitivity of FDG PET [266] [267] [268] . Kirgan et al. [269] demonstrated more lesions with PET than with CT or MRI in 16/24 patients, with PET leading to a change in management in 45% of cases; in half of these, surgery was cancelled as more extensive disease was present than previously appreciated. Yao et al. [270] assessed the value of PET in initial staging as compared with other modalities in 31 patients. In 18 of these, PET provided new information and in ten it provided comparable information to all other studies combined, while in three patients it was less effective. The latter cases were brain metastases missed by the whole-body PET acquisition, but in a separate substudy brain acquisition did not miss brain lesions.
Therapy assessment. Strauss et al. [266] studied the effect of chemotherapy on FDG uptake in patients with melanoma. A slight reduction was seen at 90 min but a greater reduction occurred at 48 h, persisting for 1 week. The degree of FDG uptake reduction correlated directly with the subsequent clinical response.
In conclusion, whole-body PET with FDG appears to contribute importantly in the staging of patients with melanoma. It can detect superficial lymph node or skin lesions down to 0.5 cm or less and has high sensitivity for visceral metastases with the possible exception of pulmonary lesions. It could serve as a cost-effective onemodality follow-up technique in patients at high risk of recurrence or metastasis. Its role in detecting nodal spread early after initial detection of the melanoma appears promising but will require confirmation in selected patient groups.
Endocrine tumours
Thyroid
Diagnosis. Thyroid cancer is uncommon; however, despite its low incidence it presents frequent diagnostic problems due to the prevalence of cold thyroid nodules. Current common diagnostic modalities -clinical examination, thyroid function tests, ultrasonography and thyroid scintigraphy whether with 123I, 99mTc, 2°W1 or 99mTc-sestamibi fail to differentiate benign from malignant nodules and to provide a specific diagnosis. Fineneedle aspiration biopsy, although performed in a large number of patients, has significant limitations related to sampling errors in small turnouts. Furthermore, the small size of the collected samples makes it difficult to differentiate a follicular adenoma from a follicular carcinoma. Several authors have suggested a role for FDG PET in this differential diagnosis. Bloom et al. studied 19 patients, 12 with solitary thyroid nodules and seven with multinodular goitres, using a multislice single area non-attenuation-corrected technique [271, 272] . Four of the 12 nodules were malignant while the multinodular goitres were benign. They reported different DURs (dose uptake ratio: a semiquantitative index of FDG uptake parameter) between cancers (three papillary and one follicular) and benign nodules (eight follicular adenomas). One patient with a papillary cancer had another small focus of papillary cancer within the same lobe that was not visualized. Also an incidental papillary cancer (1 ram) in a patient with a multinodular goitre (independent from the dominant nodule) was not visualized. The authors reported no overlap in DUR values between visualized benign and malignant lesions but the separation was narrow. The uptake in cancer is quite variable and this discrimination is at variance with some other reports. For instance, Joensuu et al. [273] noted FDG accumulation in three patients with a Harthle cell carcinoma, an anaplastic carcinoma and a thyroid lymphoma but showed only slight or no retention in three papillary carcinomas. Three of eight histopathologically benign tumours also accumulated FDG. In addition, it must be mentioned that FDG uptake is not uncommonly seen in an otherwise normal thyroid for unidentifiable reasons. We therefore believe that the diagnostic application of FDG in patients with undiagnosed solitary thyroid nodules is not currently warranted.
Postoperative staging. Imaging of metastases of thyroid carcinoma with FDG was first performed by Joenssu and Ahonen [274] . They studied three patients with multiple metastases of thyroid carcinoma (one papillary and two follicular) using a specially modified gamma camera (1-inch crystal and special collimator). Metastases that accumulated only FDG, only iodine or both iodine and FDG could be demonstrated. Metabolic heterogeneity was seen between different metastases in all patients. FDG accumulation may also differ between different metastases of the same patient. The uptake of FDG in metastases was shown to increase in parallel with their progression. They concluded that metastases that accumulate FDG but net 13ii may behave more aggressively than metastases that accumulate 131I but not FDG.
Metabolic heterogeneity was confirmed by Fridrich et al. [275] , Scott etal. [276] and Feine et al. [277] . Fridrich studied 12 patients with known thyroid carcinoma and suspected metastases prior to iodine therapy. FDG demonstrated 29 lesions, whereas diagnostic iodine scintigraphy (5 mCi 131I) revealed only ten. FDG demonstrated more lesions in nine patients. Post therapy iodine imaging (100 mCi 131I) confirmed positive uptake in 20 lesions. Iodine scintigraphy is insufficient to exclude the presence of metastases that may respond to 131I therapy. A positive FDG finding without iodine uptake after 131I therapy should lead to another therapeutic strategy.
In 24 patients with differentiated thyroid carcinoma, Feine etal. [277] reported an alternating ("flipflop") pattern of metastases with either 131I or FDG uptake. The FDG uptake showed an inverse proportionality to iodine uptake and to tumour differentiation. Grunwald et al. interpreted increased glucose metabolism as a sign of higher malignancy [278] .
Sisson etal. [279] reported a patient with a pulmonary metastasis from papillary thyroid carcinoma. This tumour barely concentrated 131I but was well seen using FDG. FDG uptake was lower after T 4 therapy and reduction in the TSH level. Sissons et al. suggested the use of FDG uptake measurement as a means to optimize T 4 treatment level and TSH suppression in patients with thyroid metastases unlikely to respond to t3~I, external beam radiation or surgical resection.
Preoperative staging. The annotated bibliography compiled by the Western PET Association suggests preoperative staging as another potential role for PET in patients with thyroid cancer [280] . Indeed, it would be useful to document the presence of metastases prior to surgery for consideration of surgical resection rather than subsequent radioiodine treatment. However, no published report addresses this issue.
Parathyroid
Conflicting reports are available on the role of FDG PET in localizing abnormal parathyroid tissue. Neumann et al. [281] , using attenuation-corrected regional body PET, described correct localization of 17 of 18 parathyroid adenomas and two of four hyperplastic glands in 17 patients. There were three false-positive findings including 1659 two follicular adenomas. Sisson and others, however, have reported negative results [282] . They studied seven patients with documented parathyroid adenomas and one with a recurrent hyperplastic gland (weight 0.15-4.5 g). Even in retrospect no focus of FDG radioactivity could be found to represent the abnormal parathyroid gland, and this concurs with our experience.
Adrenals
There are few reports on adrenal imaging with PET. One report has concerned the detection of medullary phaeochromocytoma while another has evaluated the role of PET in differentiating indeterminate adrenal mass in patients with cancer [121, 283] . No report has as yet dealt with the diagnosis of hyperfunctioning cortical tumours.
Phaeochromocytoma accumulates FDG and can be imaged by the PET method. Shulkin et al. have reported on two patients in whom metaiodobenzylguanidine failed to demonstrate the tumour [283, 284] . FDG PET enabled correct localization of the tumour in both cases with high contrast and should be useful in turnouts that do not accumulate MIBG. FDG also accumulates in neuroblastoma [285] .
Incidentally discovered adrenal masses are frequent. In patients with cancer, they have a 27%-36% probability of being malignant [286] . Currently, biopsy is required for differential diagnosis despite potential complications, and displays an accuracy of 80%-100% [287] . Boland etal. [121] have evaluated the ability of PET to characterize adrenal masses in patients with cancer. They reported on 24 adrenal masses in 20 patients. PET helped in the correct differentiation of benign from malignant adrenal lesions in all patients. The SUV values ranged from 2.9 to 16.6 in the 14 malignant lesions and from 0.2 to 1.2 in the ten benign lesions. Although a larger sample size is required to confirm these observations, FDG PET appears promising for the evaluation of incidentally identified adrenal masses in patients with cancer.
Neuroendocrine tumours
Endocrine pancreatic tumours can be visualized by PET. According to Ahlstr6m etal. [288] , 11C-5-HTP displays higher uptake than does ~1C L-dopa in secreting tumours but these amino acid precusors appeared less useful than CT for the detection of non-functioning tumours. Little experience is available concerning the use of FDG in endocrine pancreatic tumours. In our hands [289] , FDG has appeared useful for the detection of carcinoid and neuroendocrine tumours as it demonstrated more lesions than indium-octreotide in six patients studied. The FDG uptake varied markedly from patient to patient, however, possibly reflecting the metabolic activity of the tumour. In a subsequent patient with octreotide-demonstrated gastrinoma, FDG PET was completely normal.
Pituitary tumours
Pituitary adenomas have been more frequently studied with J tC-methionine or with dopamine D 2 receptor binding ligand (for functioning prolactinomas). In the experience of Murh et al. [290] and Bergstr6m et al. [291] , all untreated pituitary adenomas studied demonstrated high FDG uptake, similar to or higher than normal brain tissue. The tumour to brain ratio was, however, higher for methionine. Also the variability of FDG uptake in nonsecreting adenomas was higher than that of llC-L-methionine and the correlation with hormone secretion was less good. Dopamine agonist treatment seemed to reduce FDG uptake as well as methionine uptake. FDG uptake in meningioma was considerably lower than in pituitary adenomas and this feature could be used for differential diagnosis. Although most cases can be effectively diagnosed using more conventional imaging, PET may have a role in selected instances.
Musculoskeletal neoplasms
Musculoskeletal tumours were among the first non-brain turnouts to be imaged by PET. Kern et al. [292] reported on four patients with soft tissue tumours and one with osteogenic sarcoma. As in the brain, a correlation between the grade of the turnout and the extent of FDG uptake was noted in these patients. This observation was confirmed by Adler et al. [37] in five patients with liposarcoma of the thigh. DUR averaged 1.38 in low-grade and 2.45 in high-grade tumours, suggesting a role of FDG in this metabolic distinction. Adler et al. [38] extended this observation in 25 patients presenting six benign lesions and 19 malignant lesions of various grades. High-grade malignancies had DUR values >1.6 while lesions with values <1.6 were either benign or low grade. In a recent study, Nieweg et al. [293] examined the correlation between tumour grade and FDG metabolic rate (regional glucose metabolic rate and SUV). They studied 18 patients with soft tissue sarcomas and four with benign soft tissue lesions. All sarcomas were clearly visualized, as was one benign lesion. An equivocal scan was obtained in another benign lesion. A correlation was found between glucose metabolism and the histopathological malignancy grade. Such a correlation was not demonstrated for the SUV (calculated as turnout average). Benign lesions could be distinguished from highgrade malignant lesions but not consistently from lesions with low or intermediate malignancy grades.
Preoperative diagnosis and staging. The clinical impact of PET imaging in soft tissue masses was explored by Griffeth et al. [294] . They performed limited axial field of view scanning in 19 patients with ten malignant and ten benign lesions. DUR values provided complete discrimination between benign and malignant lesions. Most patients undergo an extensive evaluation before surgical diagnosis with the goals of evaluation of the nature of the primary lesion, assessment of local invasion and extension, and detection of possible distant metastases. All questionable lesions must be presumed malignant before definitive surgery as there is reluctance to violate tissue planes for simple biopsy. Definitive diagnosis is frequently only made at complete or radical surgical resection to avoid seeding or contamination of adjacent tissue planes with malignant cells.
Current results support the use of PET to help in this preoperative diagnosis even though accuracy cannot be expected to be 100% and the method of quantification must be better standardized [78] . For those lesions shown to be malignant, PET may also aid in the preoperative planning of biopsy and therapy. Indeed, it provides information regarding the distribution of metabolically active tumour tissue relative to the abundant necrotic, oedematous, inflammatory or postoperative changes in otherwise normal surrounding tissue. PET appears more accurate that CT or MRI in the selection of sites with the greatest concentration of cellular neoplastic elements for histopathological analysis. In this indication PET may be particularly useful in patients with previous surgery, chemotherapy or radiation therapy that has resulted in anatomical changes and distortion of normal planes [295, 296] . It can predict the benign nature of recurrent masses or allow a conservative biopsy and monitor approach rather than extensive surgical excision of suspicious but potentially benign tissues.
PET also aids in the detection of regional or distant metastases [293] . In the latter study, 12 suspicious lymph nodes (1-2 cm in diameter) were confirmed as metastatic while four normal size involved lymph nodes were identified. Metastatic mediastinal lymph nodes and an unsuspected primary leiomyosarcoma of the oesophagus were also diagnosed.
PET can be useful to detect the presence of residual or recurrent malignant disease after surgery. In osteogenic sarcoma, detection of pulmonary metastases can also be performed using lSF-fluorine ion to identify an extraosseous site of bone formation or calcification [297] .
Finally, Nieweg et al. report on the role of FDG PET in evaluating the results of isolated limb perfusion therapy in a patient with a locally advanced liposarcoma. Before perfusion, a high glucose consumption of the tumour was demonstrated which was absent after perfusion of TNF-o~, interferon-gamma and melphalan. Subsequent excision confirmed complete necrosis of the tumour [295] .
Ovarian carcinoma
Ovarian carcinoma is the leading cause of death among gynaecological tumours [298] . It has spread throughout the pelvis in about two-thirds of all patients at the time of diagnosis. Non-invasive staging is usually performed using the clinical examination, ultrasonography, urogra- phy and tomodensitometry. The search for lung and pleural metastases as well as for hepatic metastases is systematic. Confirmation of the disease and definition of its true extent is usually not complete until the time of initial surgery. Therapy after careful evaluation of the lesion consists in maximum early resection followed by chemotherapy and/or radiotherapy. Post-therapy followup is facilitated by monitoring tumoral markers, especially CA 125 (but also CEA and alpha-fetoprotein or ~-HCG in specific tumours, i.e. yolk sac tumours and choriocarcinoma); CA 125, however, is not elevated in all patients with residual or recurrent tumours. Mortality after surgery and radio-or chemotherapy remains high. Indeed, even after negative second-look surgery, recurrences occur in 40%-63% of cases [298] . These recurrences and the mortality primarily result from occult metastases involving the peritoneal surfaces of the pelvis and abdomen and the retroperitoneal lymph nodes. Unfortunately, current diagnostic techniques, including CT or MRI and laparoscopy or culdocentesis, lack sensitivity and specificity for accurate diagnosis and staging of primary and residual or recurrent disease. New methodologies are needed to optimize treatment planning in ovarian carcinoma [153] and FDG PET has been evaluated. Successful imaging of ovarian cancers with FDG was first reported by Wahl et al. [299] . The largest experience has been reported by Hubner et al. [300] . These authors presented data from an extended series at the ICP meeting [301] . Ninety patients presenting with ovarian masses were studied by limited field or whole-body PET and CT prior to laparotomy for suspected ovarian cancer. High sensitivity and specificity (89% and 92%) were reported, with high positive and negative predictive values (94% and 85%). PET identified occult foci of active tumour not apparent on morphological studies (CT sensitivity 72%, specificity 43%) ( Table 8) . Data in recurrent disease were available in 44 cases. Again, high sensitivity and specificity were demonstrated (94% and 100%).
Other groups have concentrated on patients suspected of recurrent disease. Karlan et al. [302] performed whole-body studies in 12 patients prior to second-look surgery. PET-defined disease in six patients was confirmed by surgery. Six patients with negative scans had no visible disease at surgery; however, in five of these patients microscopic disease was defined by pathology. Casey et al. [303] described 19 patients with suspected recurrent tumour after initial surgical resection (based on clinical signs or biology). The final diagnosis was established by surgery or clinical follow-up. FDG demonstrated 10 of 11 histologically proven tumours, and there was one false-positive result. Sensitivity was 91% and specificity 88%, versus 55% and 75% for CT and 73% and 100% for tumour markers. Two patients with metastatic liver lesions were also detected by PET. Results of Avril et al. [304] , however, draw attention to the lack of specificity of FDG in patients with pelvic abcesses or inflammatory foci.
PET and FDG appear useful to guide surgery through a more complete staging of abdominal and extra-abdominal tumours, and to avoid second-look surgery, e.g. in cases of extensive dissemination.
Genito-urinary neoplasms
Few reports have been devoted to the use of FDG PET in patients with genito-urinary neoplasms. The available reports, however, are rather encouraging. Imaging of kidney cancer using FDG has been reported by several groups [305, 306] . Prolonging the delay between injection and imaging is frequently sufficient to allow adequate contrast for tumour imaging. Wahl et al. [306] have presented results of pilot animal and human studies. They have demonstrated both adenocarcinomas and transitional cell carcinomas, but the place of PET in the diagnosis and staging of these tumours remains to be defined.
Bladder cancer can also be demonstrated using FDG [307] . Visualization of the primary tumour is possible provided the urinary activity has a low concentration. Regional nodal disease can also be demonstrated [308] , preferably using iterative reconstruction techniques. Harney et al. [307] have reported successful detection of distant metastasis.
PET also appears effective for the visualization of testicular carcinoma and in particular germ cell carcinoma [309] . In a study of 21 patients with stage II-IV testicular germ cell turnouts, Wilson et al. [310] evaluated various clinical PET indications using a multiwire proportional PET system and FDG. Despite the limited sensitivity and resolution of such a system, they provided convincing arguments for its value in detecting metastatic disease (active disease >2 cm in diameter). In patients with malignant teratoma and residual masses after chemotherapy, PET differentiates well-differentiated teratoma, benign lesions and fibrosis from poorly differentiated viable malignant tumours. Surgery of differentiated teratoma remains indicated, however, as relapse is not infrequent (12%). Determination of the nature of residual masses might be more important in seminoma. Finally, PET and FDG appear useful to follow up the results of therapy. Confirmation in a larger number of patients and using a more quantitative technique is needed.
Results in prostate cancer have been less favourable [311] . Several preliminary reports suggest that PET misses a significant number of primary tumours and nodal metastases [312] . Furthermore, data from Shreeve et al. [131] suggested that close to 50% of patients with metastatic prostate carcinoma do not have their bone lesions visualized by FDG PET.
Brain tumours
Most PET studies performed for the evaluation of brain tumours concern gliomas, the most frequent type of primitive brain tumours. According to the W.H.O. classification, gliomas include four malignancy grades corresponding to different therapeutic indications and prognosis.
Differential diagnosis. When lesions are demonstrated
by CT or MRI with contrast enhancement and peripheral oedema, differential diagnosis usually has to be made between a tumour and an abscess: PET shows high FDG uptake in tumoral lesions (especially high-grade lesions) [11, 33, 314] , and no or low uptake of FDG in abscesses; however, in some cases, tumours, even high-grade gliomas, may exhibit low FDG uptake, whereas some abscesses may exhibit high uptake of FDG [315] or 11C-methionine (MET) [316] . In patients with AIDS, FDG PET has proved useful to differentiate between brain lymphoma and non-malignant lesions such as toxoplasmosis or syphilis [317] .
Dethy et al. studied the use of PET with FDG or MET in patients with chronic brain haematomas [318] , and observed moderate uptake of both tracers in examinations performed 20-32 days after the initial symptoms. PET was not helpful at that time in differentiating between neoplastic and non-neoplastic origins of an intracerebral haematoma. However, the uptake of both tracers decreased 76-103 days after the initial symptoms, and PET might then be useful in detecting a tumour underlying the haematoma.
When CT or MRI shows a non-enhancing lesion, the differential diagnosis must usually be made between a low-grade glioma and a non-tumoral lesion such as gliosis, post-traumatic scar tissue, or even sometimes an ischaemic lesion. While in some cases of low-grade gliomas PET may show increased FDG uptake, in most cases FDG uptake is decreased [11, 33, 314] , as in nontumoral lesions. In these cases, MET is very helpful, as the uptake of MET is increased in nearly all low-grade gliomas as well as in high-grade gliomas [319] [320] [321] [322] [323] . PET is, however, unsuccessful in differentiating between the various histological types of brain tumours, as high uptake of FDG is seen not only in gliomas but also in lymphomas [317, 324, 325] , meningiomas [326] , pituitary adenomas [327] and metastases [328] .
In difficult cases, PET, performed in stereotactic conditions if necessary, can help to select the best site to perform a biopsy [329] [330] [331] [332] [333] [334] . Levivier et al. [331] showed that the number of non-diagnostic trajectories of stereotactic biopsies was smaller if the target was defined by PET and CT rather than by CT alone. In lowgrade lesions, where FDG uptake is usually low, MET or 11C-tyrosine may be useful in detecting the best site for biopsy.
Preoperative staging. Primitive brain tumours are usually unifocal and do not metastasize. Staging therefore mainly concerns prediction of the grade of malignancy, delineation of the tumour, and determination of turnout heterogeneity.
Since the initial description of the use of FDG PET in cerebral gliomas by Di Chiro et al. [33] , a lot of studies have been performed, and have drawn the same conclusions: There is a clear correlation between the uptake of FDG and the histological grade of gliomas, and also between the uptake of FDG and the survival prognosis [ 11, 314, [335] [336] [337] . The usual visual pattern is a hot spot in high-grade lesions, and a cold spot in low-grade gliomas; however, a cold spot may be seen in some highgrade gliomas; on the other hand, the presence of a hot spot in a low-grade glioma is usually an indicator of malignant degeneration [338] . The same correlations are found when the ratio between tumour and the normal contralateral cortex (T/CTX ratio) is considered. Patronas et al. [339] postulated that within high-grade gliomas, the uptake of FDG might be a more important prognostic factor than the histological grade, but most of the cases included in this study were already recurrences.
The absolute values of glucose consumption are also correlated with the histological grade of gliomas, but there is some overlap between the grades, and most authors consider that, for clinical use, these calculations do not yield more information than visual analysis combined with a semi-quantitative evaluation of the T/CTX ratio. Moreover, the principle of quantitative glucose consumption calculation is cdntroversial in brain tumours [11, [340] [341] [342] , and results can be modified by some medications such as corticosteroids [343] or barbiturates [344] . Patients usually fast for 4-6 h before the PET examination, but Ishizu et al. [345] have calculated that glucose loading decreases FDG uptake in the normal cortex more than in the turnout, resulting in an increased T/CTX ratio by 26%. In a study concerning grade II and III gliomas, Herholtz et al. [346] found a clear correlation between the uptake of FDG and the tumour cell density evaluated by multiple stereotactic biopsies.
One exception to the correlation between FDG uptake and malignancy is the juvenile pilocytic astrocytoma, a very benign lesion. Fulham et al. [347] found a high up-take of FDG in these lesions, higher than in other lowgrade astrocytomas and equivalent to that in anaplastic astrocytomas. It is also known that these lesions usually exhibit contrast enhancement on CT or MR/. These "pseudo-malignant" features of a typically benign lesion are interpreted to reflect the unusual vascularity of pilocytic astrocytomas, while the increased glucose utilization rate might be related to expression of the glucose transporter.
FDG PET can also show remote metabolic effects based on deafferentation by the lesion. A depressed cerebellar glucose metabolism (cerebellar diaschisis) contralateral to brain tumours (or other lesions) usually occurs when they invade the motor cortex or the thalamus [348] .
Methionine studies in brain gliomas have also shown a correlation between the uptake of this tracer and the histological grade, but to our knowledge no correlation has been reported between the uptake of MET and prognosis [320, 322, [349] [350] [351] [352] . Few studies have compared FDG and MET; they have demonstrated that FDG is probably better for establishing the degree of malignancy, whereas MET better delineates the lesions, especially low-grade gliomas [319, 321, 323, 353, 354] .
In meningiomas, Di Chiro et al. [326] found a correlation between the tumoral glucose utilization, the malignancy and the probability of recurrence. There was also a significant inverse correlation between the glucose metabolic rate and the doubling time. The strong correlation between FDG uptake and the clinical outcome led Di Chiro et al. to conclude that the metabolic rate is at least as important as the histological classification in these tumours. Borbely et al. [355] performed FDG PET in five patients with cranial or spinal neuromas, and found a higher uptake of FDG in the case where the tumour recurred than in the other cases where the lesion was stable over time.
Postoperative evaluation of residual' tumour. CT and MRI cannot reliably differentiate the presence of residual tumour from postoperative enhancement. Glantz et al. [356] have studied tumour patients after surgery, compared them with patients operated on for epilepsy, and compared gliomas before and after corticosteroid therapy: they found that FDG uptake is not increased in the postoperative period (in epilepsy surgery or total tumour resection), is not affected by corticosteroid therapy, and accurately predicts the persistence of tumoral tissue, and thus early recurrence.
Follow-up of therapy. In rats, Ito et al. [357] showed a 15% decrease in glucose uptake by the normal brain 4 days to 4 weeks after radiotherapy. In experimental rat brain tumours, the uptake of FDG [358] and MET [359] by the tumour decreased early after irradiation, except in radioresistant tumours.
In humans, Mineura et al. [360] reported a paediatric case where a 50% decrease of FDG uptake after irradia-1663 tion was highly consistent with the period of clinical relief. After a combination of radio-and chemotherapy, Ogawa et al. [361] measured a mean reduction of glucose consumption of 41% in tumours, and of 14% in normal brain tissue. Rozental et al. found that the tumour to white matter ratio increased 20%-100% 24 h after chemotherapy [362] , and then decreased to between 22% above and 35% below baseline 28 days later. HNzer et al. [363] found no differences between FDG PET before and 6 and 12 months after radiochemotherapy in 15 glioblastomas. However, to our knowledge, no correlation has been demonstrated between prognosis and an early PET modification after treatment.
In posterior fossa tumours and primitive neuroectodermal tumours, Holthoff et al. [364] found a good correlation between the modifications of FDG uptake before and after treatment and the neuroradiological findings. FDG PET also corresponded to the duration of initial clinical improvement.
Differential diagnosis between tumour recurrence and radiation necrosis. It is most often impossible to make this differential diagnosis by CT or MR/in those patients who have been operated on and then treated by radiotherapy, and present a few months later with a partially necrotic lesion and peripheral contrast enhancement. FDG PET proved useful in these cases to differentiate tumour recurrences exhibiting a high uptake of FDG from radiation necrosis in which the uptake of FDG is low [356, [365] [366] [367] . In this indication, FDG PET proved superior to rubidium-82 PET [367] . Some false-negative FDG cases have been demonstrated, however, especially in recurrences of low-grade gliomas but also in histologically proven recurrences of high-grade gliomas. Some false-positive cases have also been demonstrated [361, [368] [369] [370] [371] . Falsenegative cases may especially correspond to small lesions included in the cortex, or to partially cystic or necrotic lesions. The usefulness of FDG PET in the differential diagnosis between recurrence and radiation necrosis has also been demonstrated after interstitial brachytherapy or radiosurgery for metastases [368, 372] .
In recurrences of proven high-grade gliomas, Patronas et al. [339] identified all the tumours, and demonstrated a correlation between the FDG uptake (ratio of the tumour to the corresponding contralateral brain) and the median survival time: 19 months if the ratio was equal to or less than 1.4, compared to 5 months if the ratio was greater than 1.4. They also suggested that FDG PET in these cases could be a more important prognostic factor than histology, as the survival of patients with grade IV gliomas with a low FDG uptake was better than that of patients with grade II1 gliomas with a high FDG uptake. These conclusions were later confirmed by Alavi et al. [93] , who observed a median survival of 7 months for the hypermetabolic tumours, compared to 33 months for the hypometabolic lesions.
In a few studies performed with MET, this tracer also proved useful in detecting biologically active residual or recurrent brain tumours, and could yield less false-negative results than FDG PET [369, 373, 374] . In our experience, MET proved much better than FDG in delineating tumour recurrences, and usually clearly depicted low-grade lesions and some high-grade lesions that were not seen with FDG [354] ,
How to improve clinical PET
The use of 3D-imaging techniques and of large field of view detectors has considerably increased system sensitivity and reduced statistical noise, thereby improving clinical PET.
Reduction in image artefacts can be obtained through transmission correction, iterative reconstruction and better patient preparation. Attenuation correction, up to now impractical for whole-body imaging (due to the excessive duration of transmission acquisition), will become possible with the use of a single-photon emitter (137Cs). Furthermore, the use of transmission image segmentation has been shown to decrease statistical noise and improve the quality of image reconstruction. Maximum likelihood iterative reconstruction also decreases artefacts, especially in areas of high heterogeneous count activity, and can facilitate image interpretation. Improved speed of computing and better algorithms make these easier to use in clinical practice. Finally, better patient preparation, adequate fasting, glucose level verification, adequate relaxation or use of diazepam as a muscle relaxant and use of forced diuresis for pelvic examination (furosemide) can also contribute to the quality of the examination.
Interpretation can also be improved by anatomical correlation, in particular through the use of image fusion with structural images. Accurate quantification could also significantly contribute to interpretation. Most important, however, is patient selection. As FDG is a nonspecific tracer, its accuracy depends on proper patient selection. Inclusion of patients with low disease probability increases the likelihood of false-positives, and the technique is not suited to unselected screening. However, in adequately selected groups with proper diagnosis verification, the technique has been shown to have a considerable impact.
